DSSG Group: Breast

Women with localised recurrent or new primary breast cancer in the previously irradiated breast

The purpose of this study is to evaluate the toxicity associated with a 1-week ultra-hypofractionated partial breast irradiation (rPBI) regimen following breast-conserving surgery (BCS) for local recurrence or new primary breast cancer in the previously irradiated breast (LR).

Newly diagnosed breast cancer patients and patients with a diagnosis of breast cancer brain metastasis (BCBM).

The purpose of this study is to use an assay (the Illumine TruSight Oncology 500 assay) to determine gene mutations in people with new diagnosed breast cancer, as well as people with recurrent and stage IV brain metastatic breast cancer.

Oligometastatic Breast Cancer (OMBC)

To determine if the addition of SABR treatment towards the oligometastatic sites in addition to the standard first-line treatment of care can improve progression-free survival (PFS) for patients.

Triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery

to compare the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician’s choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery

Breast cancer patients over 16 years old, male or female with central nervous disease.

PRIMROSE Cerebrospinal Fluid (CSF) Study aims to collect and investigate CSF samples and related data from patients with central nervous system disease secondary to breast cancer.

High-risk early triple negative breast cancer (TNBC) without mutations in the BRCA1 or BRCA2 gene. For this study high-risk early TNBC is defined as any presence of TNBC that still remains in the breast or lymph node tissue after receiving treatment and undergoing surgery.

The purpose of this study is to see if sacituzumab govitecan in combination with pembrolizumab can improve outcomes and delay the return of disease in patients with high-risk early TNBC when compared to pembrolizumab alone or pembrolizumab in combination with capecitabine.

ER+/HER2- early-stage breast cancer with ctDNA relapse.

To evaluate whether elacestrant can delay occurrence of distant metastasis or death when compared to standard endocrine therapy in ER+/HER2- patients with ctDNA relapse.

Early or metastatic triple negative breast cancer (TNBC)

The main purpose of this study is to profile exosomes isolated from the plasma of women diagnosed with TNBC during routine treatment and follow up in the oncology clinic using Nanoparticle tracking analysis (NTA) and Raman/infra-red spectroscopy.